CHARLOTTETOWN, PEI – BIOVECTRA was recently named to Communitech’s True North list as one of Canada’s high performing tech companies that has a promising growth trajectory. Team True North is a roster of Canadian innovation companies shown by verified data to have the highest probability of reaching $1B in revenue. As global markets experience […]
Charlottetown, P.E.I. (April 14, 2022) – BIOVECTRA broke ground today, with help from provincial and federal officials, on a cutting-edge facility that will manufacture mRNA vaccines and therapeutics starting in 2023. BIOVECTRA’s mRNA Vaccine and Biomanufacturing Centre will add 36,000 square feet to its existing Charlottetown campus and, when operational, the cGMP facility will […]
Charlottetown, P.E.I. (November 18, 2021) – BIOVECTRA today announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada. This exciting new capability will result from a joint private-public investment made by BIOVECTRA and the […]
Charlottetown, P.E.I. (November 12, 2021) – BIOVECTRA is proud to be selected as one of Canada’s Top 100 Employers for 2022 and considered amongst some of the country’s leading workplaces. As one of four Atlantic Canadian companies selected, BIOVECTRA is a fast growing, forward-thinking, global pharmaceutical contract development and manufacturing organization (CDMO) solving complex challenges […]
Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors. “Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board […]
For immediate release ABEC’s Custom Single Run (CSR) fermentation solutions offer working volumes up to 1,000 liters Bethlehem, PA, USA, and Charlottetown, CANADA, September 20, 2021 – ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing and BIOVECTRA, a CDMO specializing in clinical-to-commercial scale production of high-quality regulated Biologics, Active Pharmaceutical Ingredients, […]
MALVERN, Pa. & SAN DIEGO — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company […]
Charlottetown, PE – Today the Future Skills Centre (FSC) announced the investment of $1.5 million to support the establishment of the Canadian Alliance for Skills […]
BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital […]
Statement from BIOVECTRA President, Oliver Technow, on BIOVECTRA’s sale to H.I.G. Capital: “We are very excited to enter into this new chapter with H.I.G. Capital! Under their stewardship we have a fantastic opportunity to continue building and growing our business right here in Atlantic Canada.” Official press release: Mallinckrodt Agrees to Sell BIOVECTRA Inc. to […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.